PRS-220

PRS-220 is an inhaled Anticalin protein therapeutic that targets connective tissue growth factor (CTGF, also known as CCN2). It was developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases. CTGF is a key driver of fibrotic tissue remodeling in IPF, and overexpression in lung tissue contributes to disease progression. By inhibiting CTGF, PRS-220 aims to reduce the decline in lung function associated with IPF. The drug leverages Anticalin technology, which produces small (~20 kDa), engineered proteins designed for high-affinity target binding and suitability for inhaled delivery. Preclinical data demonstrated superior potency and lung biodistribution compared to systemically administered anti-CTGF monoclonal antibodies such as pamrevlumab[1][4][5][6].